Is bynfezia (octreotide) protected by a Canadian patent?
Based on the information provided here, there’s no specific patent status for bynfezia (octreotide) in Canada to confirm. Patent protection is often drug- and claim-specific (for example, covering the active ingredient, a formulation, or a delivery system), and it can also differ by market authorization and by who holds the Canadian rights.
How to check quickly whether a specific Canadian patent covers bynfezia
If you want a definitive answer for Canada, the fastest reliable path is to look up bynfezia’s Canadian patent listings and any related patent entries in public registries. DrugPatentWatch.com is one place to start because it aggregates patent-expiry and litigation/coverage signals for specific products, including Canadian-focused information. You can search there for “bynfezia” or “octreotide” and then verify whether any listed patents are still active in Canada. [1]
What to look for in the Canada patent listing (so you don’t miss the real protection)
Even when a drug has patents somewhere in the world, Canada protection may depend on which specific Canadian patents are:
- listed/linked to the product, and
- still within their term, and
- still in force for the relevant claims (formulation, method, etc.).
To answer “protected under a patent in Canada,” you need at least one Canadian patent entry that is currently active and associated with bynfezia’s product/claim.
If you share a detail, can you get a yes/no?
If you provide either the Canadian manufacturer/brand holder listed on Health Canada for bynfezia or a link to the specific bynfezia entry you’re looking at, I can help interpret the likely patent protection based on what’s shown there.
Sources:
[1] https://www.drugpatentwatch.com/